@SCOTUSblog So how does this jibe with the SCOTUS claim that race is not a factor in elections. Race counts in one place, but not another? Somebody help me clarify the principals that are being applied.
@DrOzCMS You know, but it has not been said loudly enough, the payers and especially the pharmacy benefit managers,have done more to make drugs less affordable than any drug company. Also - making pharma charge less in the US will then make life saving drugs unaffordable in the 3rd world.
I'm excited to be part of this upcoming live discussion on MEK Inhibitors in Neurofibromatosis Type 1 presented by @cec_onc! Tune in online on 5/8 at 12:15p ET & earn 1.0 free #CME/CE credit ➡️ https://t.co/j3raRC5vgY #MedX#MedEd
I hope that these data will help to bring mirdametinib to people living with neurofibromatosis, type 1. Thank you to SpringWorks Therapeutics, my co-authors, and the patients and families who contributed their time and effort to making this clinical trial successful.
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma | Journal of Clinical Oncology https://t.co/Wn2Fnjuom0
I am honored to be lead author on this publication.